Literature DB >> 20454875

Myocardial washout of 99mTc-tetrofosmin and response to steroid therapy in patients with cardiac sarcoidosis.

Hirokazu Kudoh1, Sei Fujiwara, Hideyuki Shiotani, Hiroya Kawai, Kenichi Hirata.   

Abstract

OBJECTIVE: Early diagnosis and initiating treatment of cardiac sarcoidosis are essential because cardiac involvement is an important prognostic factor. Although there are many reports on the diagnosis of cardiac sarcoidosis, the literature on predicting the efficacy of steroid therapy is very limited. The purposes of this study were to investigate the myocardial washout of (99m)Tc-tetrofosmin (TF), and to evaluate the predictability of left ventricular (LV) functional recovery after steroid therapy in patients with cardiac sarcoidosis.
METHODS: We performed TF-gated SPECT and echocardiography for ten patients with cardiac sarcoidosis before and after initiating steroid therapy. SPECT images were acquired at 30 min (early images) and 3 h (delayed images) after injection. We calculated the total defect score (TDS) and left ventricular ejection fraction (LVEF). The washout score (WOS) was considered as the difference between the early and delayed TDS. In addition, we defined DeltaLVEF as the change in LVEF after initiating steroid therapy. Furthermore, we analyzed the regional TF myocardial uptake (%uptake) and the regional LV function (wall thickness, WT) by the 20-segment model on polar maps as regional indices. The regional washout (RWO) was defined as the change in %uptake between the early and delayed images in TF SPECT before the therapy. We calculated the improvement factor of the regional LV function as DeltaWT (WT after initiating therapy - WT before the therapy) and investigated the relationships among the indices.
RESULTS: We observed WO in 6 of 10 patients (60%). Decreased WT on echocardiography was observed in only 2 of 6 patients (33.3%) in the WO(+) group and in all 4 patients (100%) in the WO(-) group (p < 0.05). WOS before initiating steroid therapy exhibited a good correlation with DeltaLVEF (r = 0.685, p < 0.05). In the regional analysis, %uptake in the early images and delayed images before therapy did not significantly correlate with DeltaWT. In contrast, RWO before therapy was well correlated with DeltaWT (r = 0.435, p < 0.05).
CONCLUSION: Our preliminary study shows that there is a relationship between washout of (99m)Tc-tetrofosmin and the LV functional recovery after steroid therapy in patients with cardiac sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20454875     DOI: 10.1007/s12149-010-0376-8

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  8 in total

Review 1.  Update on Treatment in Cardiac Sarcoidosis.

Authors:  Laura Young; Brett W Sperry; Rory Hachamovitch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

2.  Controversies in the Treatment of Cardiac Sarcoidosis.

Authors:  Ogugua Ndili Obi; Elyse E Lower; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

3.  Relationship of decreased accumulation of (99m)Tc-tetrofosmin on myocardial single-photon emission computed tomography images between QRS duration in dilated cardiomyopathy patient with left bundle branch block.

Authors:  Sachiko Takamine; Sei Fujiwara; Mayumi Shigeru; Tatsuro Ito; Hiroya Kawai; Hideyuki Shiotani; Ken-ichi Hirata
Journal:  J Nucl Cardiol       Date:  2014-06-19       Impact factor: 5.952

Review 4.  Atrial Fibrillation in Cardiac Sarcoidosis.

Authors:  Davendra Mehta; Jonathan M Willner; Philippe R Akhrass
Journal:  J Atr Fibrillation       Date:  2015-12-31

Review 5.  Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner?

Authors:  Irving E Perez; Mario J Garcia; Cynthia C Taub
Journal:  Curr Cardiol Rev       Date:  2016

6.  (99m)Tc-MIBI Washout Rate to Evaluate the Effects of Steroid Therapy in Cardiac Sarcoidosis.

Authors:  Masayoshi Sarai; Sadako Motoyama; Yasuchika Kato; Hideki Kawai; Hajime Ito; Kayoko Takada; Ryuji Yoda; Hiroshi Toyama; Shin-Ichiro Morimoto; Yukio Ozaki
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013

7.  Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis.

Authors:  David G Rosenthal; Purvi Parwani; Tyler O Murray; Bradley J Petek; Bryan S Benn; Teresa De Marco; Edward P Gerstenfeld; Munir Janmohamed; Liviu Klein; Byron K Lee; Joshua D Moss; Melvin M Scheinman; Henry H Hsia; Van Selby; Laura L Koth; Miguel H Pampaloni; Julie Zikherman; Vasanth Vedantham
Journal:  J Am Heart Assoc       Date:  2019-09-06       Impact factor: 5.501

8.  Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review.

Authors:  Siavosh Fazelpour; Mouhannad M Sadek; Pablo B Nery; Rob S Beanlands; Niko Tzemos; Mustafa Toma; David H Birnie
Journal:  J Am Heart Assoc       Date:  2021-09-02       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.